Oa Magbagbeola

Abstract 4456: Preliminary investigation of the promoter methylation status of BRCA1, BRCA2, TP53 genes of some breast cancer patients

Epigenetic alterations in BRCA1, BRCA2 and TP53, such as DNA methylation, may be an effective approach in diagnosis, prognosis and therapy in breast cancer. This study examines the DNA methylation signature of BRCA1, BRCA2 and TP53 in some breast cancer patients attending a Clinic in Lagos, Nigeria. In this study, 14 blood specimens with Invasive Ductal Carcinoma (IDC) were investigated. The samples were modified by Bisulfite modification, and then assessed by Methylation-Specific PCR (MSP). The methylation analysis indicates that 7(50%) of the 14 patients had a segment of the promoter region of BRCA1 gene methylated, 8 (57.14%) of BRCA2 methylated and 11(78.57%) of TP53 promoter region. This study provides preliminary evidence for the gene expression inactivation of BRCA 1, BRCA 2, and TP53 Genes in over 50% of the 14 patients with Stage 2 invasive ductal carcinoma who participated in this study. Citation Format: Titilola A. Samuel, babatunde ayo james, Muhammad HABEEB, temitope oshodi, olubunmi magbagbeola. Preliminary investigation of the promoter methylation status of BRCA1, BRCA2, TP53 genes of some breast cancer patients. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4456.